

# PORI REGISTRY: A 36-MONTH FOLLOW-UP (BAS Vs PES Vs BMS)\*

## PURPOSE

To compare clinical outcomes of Titanium-Nitride-Oxide Coated Stents, Paclitaxel Eluting Stents and Bare Metal Stents in routine clinical practice.

## METHODS

- Between May 2003 and November 2004, all consecutive patients scheduled for stent implantation were considered for this registry.
- The 519 patients who were MACE free at the term of Clopidogrel discontinuation were followed for an additional 12 months, to evaluate the late thrombotic events : Death / Cardiac Death / MI / TLR / Thrombosis / MACE.

## RESULTS

### Baseline Clinical Characteristics

	TITANOX (201)	PES (204)	BMS (184)
Age (years)	67 ± 10	64 ± 10*	68 ± 10
Men, n (%)	143 (71)	147 (72)	120 (65)
Diabetes, n (%)	34 (17)	37 (18)	45 (24)
Current smoking, n (%)	58 (29)	53 (26)	44 (24)
Hypercholesterolemia, n (%)	181 (90)*	167 (82)	147 (80)
Hypertension, n (%)	133 (66)*	110 (54)	107 (58)
Medical Treatment, n (%)			
Acetylsalicylic acid	189 (94)	190 (93)	175 (95)
β-Blockers	152 (76)	160 (78)	147 (80)
ACE inhibitor	33 (16)	36 (18)	37 (20)
Lipid-lowering agents	177 (88)	164 (80)	155 (84)

\* p < 0.05

### Procedural and Lesion Characteristics

	TITANOX (218 lesions/ 221 stents)	PES (244 lesions/ 247 stents)	BMS (202 lesions/ 218 stents)
Target Vessel, n (%)			
LAD	100 (46)	124 (51)	68 (34)
LCX	48 (22)	37 (15)	57 (28)
RCA	54 (25)	68 (28)	57 (28)
Left Main	7 (3)	7 (3)	8 (4)
Bypass graft (venous)	9 (4)	8 (3)	12 (6)
Lesion Type, n (%)			
A	26 (12)	54 (22)	49 (24)
B1 / B2	137 (63)	171 (70)	145 (72)
C	55 (25)*	19 (8)	8 (4)
Thrombus present, n (%)	35 (16)	34 (14)	24 (12)

\* TITANOX vs. PES / BMS, p < 0.05

### Procedural and Lesion Characteristics

	TITANOX (218 lesions/ 221 stents)	PES (244 lesions/ 247 stents)	BMS (202 lesions/ 218 stents)
RVD, (mm)	2.95 ± 0.34	2.97 ± 0.35	3.00 ± 0.48
Lesion length, (mm)	13.1 ± 3.4	13.5 ± 4.2	13.4 ± 4.5
Stent diameter	2.98 ± 0.34	2.97 ± 0.34	3.04 ± 0.5
Stent length used	15.6 ± 3.5	21.2 ± 6.7*	16.4 ± 5.2
Direct stenting, n (%)	48 (22)	46 (19)	46 (23)
Gp IIb/IIIa inhib. n (%)	54 (27)	49 (24)	37 (20)
Clopidogrel, (months)	7.7 ± 3.3	8.2 ± 3.0	8.3 ± 3.6

\* PES vs. TITANOX / BMS, p < 0.05





\*BAS: Bio Active Stent (Titanox® Coated Stent: TITAN2)

\*PES: Paclitaxel Eluting Stent

\*BMS: Bare Metal Stent

\*Titanox is the registered trademark of Hexacath's proprietary Titanium-Nitride-Oxide coating

## RESULTS



## CONCLUSIONS

- Lower rates of recurrent MI and MACE with the use of TITANOX coated stent compared with PES or BMS,
- Very low TLR rate with the use of TITANOX coated stent (5.5%),
- Higher rates of MI and Stent Thrombosis in the PES group after the discontinuation of Clopidogrel compared with TITANOX coated stent or BMS.

## PARTICIPATING CENTER

Pori Central Hospital - Pasi P. Karjalainen, MD ; Antti Ylitalo, MD ; Jhani K. E. Airaksinen, MD.



4, Passage Saint Antoine  
92508 Rueil-Malmaison Cedex - France  
Tél. +33 (0)1 41 39 01 92  
Fax. +33 (0)1 41 39 01 93  
www.hexacath.com



Paris Cardiovascular Interventions course  
October 2007

Speaker: P. Karjalainen  
Moderator: P. Barragan